BioWorld Asia

Oct. 4, 2006

ProStrakan's Agreement With Novartis Could Reach $140M

LONDON - ProStrakan Group plc sealed a deal with a headline value of $140 million under which Novartis AG will develop antibody treatments for bone-related diseases using a ProStrakan target. (BioWorld International) Read More

Crucell Pays Acambis $16.5M To Obtain Vivotif's U.S. Rights

Study: Alzheimer's Protein Has Role In Cell Signalling

EU Pharmaceutical Forum Calls For Research Support

RNAi Deal Involves Quark, Pfizer, Atugen, SR Pharma

Roslin Institute Forms Facility For Producing Stem Cell Lines

Pharmaxon's Seed Financing For Nervous System Diseases

Gamida Cell Raises $16M To Broaden Its Programs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery

BioWorld Science

Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...